JBC Oz Biosciences

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M108340200 on November 5, 2001

J. Biol. Chem., Vol. 277, Issue 2, 1099-1106, January 11, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/2/1099    most recent
M108340200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tillmar, L.
Right arrow Articles by Welsh, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tillmar, L.
Right arrow Articles by Welsh, N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Control of Insulin mRNA Stability in Rat Pancreatic Islets

REGULATORY ROLE OF A 3'-UNTRANSLATED REGION PYRIMIDINE-RICH SEQUENCE*

Linda Tillmar, Carina Carlsson, and Nils WelshDagger

From the Department of Medical Cell Biology, Uppsala University, Uppsala S-751 23, Sweden

Received for publication, August 29, 2001, and in revised form, November 1, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Stabilization of insulin mRNA in response to glucose is a significant component of insulin production, but the mechanisms governing this process are unknown. We presently observe that insulin mRNA is a highly abundant messenger and that the content of this mRNA is mainly controlled by changes in messenger stability. We also demonstrate specific binding of the polypyrimidine tract-binding protein to a pyrimidine-rich sequence located in the 3'-untranslated region (3'-UTR) of insulin mRNA. This binding was increased in vitro by dithiothreitol and in vivo by glucose. Inhibition of polypyrimidine tract-binding protein binding to the pyrimidine-rich sequence by mutation of the core binding site resulted in a destabilization of a reporter gene mRNA. Thus, glucose-induced binding of polypyrimidine tract-binding protein to the 3'-UTR of insulin mRNA could be a necessary event in the control of insulin mRNA levels.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Glucose is the main regulator of insulin biosynthesis (1). Besides controlling insulin biosynthesis by modulating protein synthesis initiation and elongation rates (2), glucose also stimulates the production of insulin by increasing insulin mRNA levels (3). This effect is achieved by a selective stimulation of insulin gene transcription (4) as well as by an increase in insulin mRNA stability (5). However, the relative contribution of transcriptional versus post-transcriptional mechanisms to the control of insulin mRNA levels is under debate. According to the original view, insulin mRNA is a highly abundant messenger (6), which is not affected by short term glucose challenges (7), and therefore controlled to a large extent by changes in messenger stability (5). The half-life of insulin mRNA was assessed to be 29 h at a low glucose concentration and 77 h at a high glucose concentration (5). Recent observations, however, challenge this view by suggesting that insulin mRNA contents of insulin-producing cells are rapidly and dramatically increased by glucose and that this effect is mediated by stimulation of insulin gene transcription (8-10). In addition, it has also been reported that glucose destabilizes, rather than stabilizes, recently formed insulin mRNA (9).

Very little is known on the mechanisms by which glucose, according to the original view, promotes an increased stability of insulin mRNA. A recent study has identified the 3'-untranslated (3'-UTR)1 region as a critical region for glucose-mediated control of rat insulin II mRNA stability (11). We have observed that the 3'-UTR of rat insulin mRNA contains a pyrimidine-rich segment directly downstream of the coding sequence (Fig. 1A). Interestingly, similar pyrimidine-rich segments are located to the insulin mRNA 3'-UTR of several mammalian and non-mammalian species including humans (Fig. 1B). Pyrimidine-rich segments are also present in 3'-UTRs of other long-lived messengers, such as alpha -globin, (I)-collagen, 15-lipoxygenase, and tyrosine hydroxylase (TH) (Ref. 12; Fig. 1A). It appears that the 37-39-kDa poly(C)-binding protein (PCBP), also known as alpha CP or hnRNP-E, binds to the pyrimidine-rich motifs of these mRNA, thereby assembling a ribonucleoprotein complex, the alpha -complex, which results in stabilization of the mRNA (13). Another interesting pyrimidine-rich sequence-binding protein is the 56-kDa polypyrimidine tract-binding protein (PTB) (14). As other hnRNP proteins, PTB assists in processing, transport, and translation of mRNAs. However, in insulin-producing MIN6 cells PTB mRNA contents are increased 5-fold by glucose (15). This may indicate that the expression of PTB is under cell-specific control and that PTB contributes to the beta -cell phenotype as a glucose-responsive secretor of insulin.


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 1.   A, comparison of PCBP and PTB consensus binding sequences to pyrimidine-rich 3'-UTR segments of TH and rat insulin mRNA. Y denotes pyrimidines and N any nucleotide. Letters in bold mark positions of transitions or transversions that differ from the PCBP and PTB consensus binding sequences. B, comparisons of the PTB consensus binding sequence with preproinsulin mRNA pyrimidine-rich 3'-UTR sequences located downstream of end of coding sequence and upstream of poly(A) signal. Letters in bold mark positions of transitions that differ from the PTB consensus binding sequence.

The aim of the present study was first to quantify insulin mRNA in rat pancreatic islets. A high insulin mRNA content would strongly support the original view that insulin mRNA contents are mainly controlled by post-transcriptional mechanisms. Second, we aimed at characterizing the molecular event by which glucose increases insulin RNA stability. We have therefore studied the putative role of the pyrimidine-rich insulin mRNA 3'-UTR in the regulation of insulin mRNA stability.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- The RNA oligonucleotides were from Scandinavian Gene Synthesis AB (Köping, Sweden). The rabbit anti-PCBP serum was a generous gift from the laboratory of Ellie Ehrenfeld. David Helfman's and Carol Bromstycks' groups kindly supplied the mouse PTB and rabbit anti-hnRNP K antibodies.

Isolation and Culture of Pancreatic Islets-- Adult Sprague-Dawley rats, from a local colony, were used. Islets were isolated by collagenase digestion (17). The islets were cultured in RPMI 1640 supplemented with 10%, Fetal Clone II serum (Hyclone Europe Ltd., Cramlington, UK). The islets were cultured free-floating 5-10 days with the medium changed every second day (16).

Human islets were obtained from the Central Unit of the beta -Cell Transplant, Brussels, where the islets were isolated and maintained in culture as described previously (17).

Quantitative Real-time PCR-- Total RNA from 20-30 islets was isolated using the UltraspecTM Total RNA Isolation System (Biotech Laboratories, Houston, TX). First strand cDNA was synthesized using random nonamers and avian myeloblastosis virus reverse transcriptase (Promega, Madison, WI). PCR reactions were carried out with the Lightcycler real-time PCR instrument, using the Faststart DNA Master CYBR Green I kit (Roche Molecular Biochemical, Mannheim, Germany). The following primers were used: insulin forward, 5'-ACAGCACCTTTGTGGTCC; insulin reverse, 5'-GGACTCAGTTGCAGTAGTTC; beta -actin forward, 5'-GCCCTGGCTCCTAGCACC; beta -actin reverse, 5'-CCACCAATCCACACAGAGTACTTG. Unknown samples were run in duplicates against an external standard curve with known quantities of linearized pRI7 plasmid, which contains the rat insulin cDNA (18), or linearized beta -actin cDNA plasmid. The amplification efficiency was similar for the reverse-transcribed islet RNA samples and pRI7 (Fig. 2A).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Real-time PCR quantification of insulin mRNA contents. A, amplification efficiency of linearized pRI7 plasmid insulin cDNA and rat islet insulin cDNA samples in real-time PCR reactions. Series of 10-fold dilutions were analyzed in duplicates. B, precultured rat pancreatic islets were maintained for 24 h at 1.7 mM glucose and in the absence of serum. Islets, in groups of 20-30, were then stimulated for 60 min with 17 mM glucose or 5 µg/ml insulin. Insulin mRNA, beta -actin mRNA, and beta -cell number were quantified as described under "Experimental Procedures." Results are means ± S.E. for six independent observations. C, precultured rat islets were maintained for 24 h at 1.7 mM glucose and in the absence of serum. The islets were then stimulated for 24 h with 17 mM glucose or with 10% Fetal Clone II. Results are means ± S.E. for six independent observations. D, precultured rat islets were maintained for 24 h at 17 mM glucose in the presence of serum. The islets were then transferred to 1.7 mM glucose with or without the presence of 5 µg/ml actinomycin D for 16 h. Results are means ± S.E. for eight observations. * denotes p < 0.05 using Student's paired t test. + denotes p < 0.05 using one-way analysis of variance and Bonferroni's test.

beta -Cell number per islet was determined using flow cytometry. Briefly, islets were trypsinized for 5 min at 37 °C to generate free islet cells. The cells were then fixated for 5 min in 4% paraformaldehyde, permeabilized with 1% saponin, and incubated for 20 min at room temperature with a guinea pig anti-insulin antibody. A fluorescein isothiocyanate-labeled anti-guinea pig antibody was added, and the cells were analyzed in a FACSCalibur flow cytometer (Becton-Dickinson Instruments). Cells with increased FL1-fluorescence were gated and counted as beta -cells.

Electromobility Shift Assay and Cross-linking Analysis-- The following RNA oligonucleotides were used: ins-PRS, 5'-UCCACCACUCCCCGCCCACCCCUCU; ins-PRS mutant 3, 5'-UCCACCACUCCCCGCCCAAAAAUCU; and human ins-PRS, 5'-CCCCCCACCCGCCGCCUCCU. RNA oligonucleotides (1 pmol) were kinased using [gamma -32P]ATP (5000 Ci/mmol, Amersham Biosciences, Inc., Uppsala, Sweden) and bacteriophage T4 polynucleotide kinase (Sigma-Aldrich). The radiolabeled probes were purified on Chroma spin-10 columns (CLONTECH Laboratories Inc., Palo Alto, CA).

Rat islets were homogenized in 100 µl of homogenization buffer (19), by using a Pellet Pestle® Motor (Kontes, Scientific Glassware/Instruments, Vineland, NJ). The homogenates were centrifuged at 13,000 × g for 10 min. The supernatant was used as the cytosolic fraction and the pellet as the nuclear fraction. The pellet was resuspended in an equal volume homogenization buffer supplemented with 1% Triton X-100.

The RNA-protein binding reaction was performed essentially as described previously (19). To half the reactions 11 mM dithiothreitol (DTT) was added, before addition of the probe. In some cases, the reaction mixtures were divided into two aliquots, one which was cross-linked by exposed to uv radiation (5 milliwatts/cm2) for 5 min and then analyzed by reducing SDS-PAGE, the other was used directly for non-denaturing gel electrophoresis. In the latter case, the samples were applied on a 7% polyacrylamide gel and electrophoresed in 0.5 × TBE (45 mM Tris borate, 1 mM EDTA). The gel was fixated, dried, and exposed to a film overnight at -70 °C.

Elution and Analysis of Gel Slices Containing the RNA Oligonucleotide-Protein Complex-- RNA oligonucleotide-protein binding reactions were run on a non-denaturing gel, and the position of the retarded and radioactive RNA oligonucleotide-protein complex was visualized by exposing an x-ray film to the gel. The lanes were then cut in three parts: above, at, and below the RNA-protein complex position. Proteins were eluted from the gel slices in 5 mM Tris acetate, pH 8.0, 0.1% SDS, and 0.1 mM EDTA under agitation overnight. The eluates were then concentrated on Centricon microconcentrators (Amicon, Beverly, MA), and the proteins were separated on a 12% SDS-PAGE and electroblotted to a nitrocellulose filter. The filters were hybridized with the monoclonal anti-PTB 3 antibody (20). Horseradish peroxidase-conjugated anti-mouse antibody (1:1000) was used as secondary antibody, which was detected by the Amersham ECL system (Amersham Biosciences, Inc.).

Northwestern Hybridization-- Northwestern was performed essentially as described previously by others (21). Islet proteins were separated by 12% SDS-PAGE and transferred to a membrane and renatured by incubating the membrane in renaturing buffer (21) for 2 h at room temperature. The membrane was then incubated in hybridization buffer (renaturing buffer + 20 mg/ml tRNA, 1 mg/ml heparin, and 0.5 nmol of 32P-labeled RNA oligonucleotide) for another 2 h. The membrane was further washed 3 × 10 min in renaturing buffer, dried, and finally exposed to an x-ray film. The position of the radioactive band was compared with that of the PTB, which was visualized by immunoblotting, analyzed in parallel.

Construction of Reporter Gene Vectors with 3'-UTR Ins-PRS-- Double-stranded DNA oligonucleotides with the sequences of wild-type ins-PRS (5'-UCCACCACUCCCCGCCCACCCCUCU), mutant 1 ins-PRS (5'-UCCACCACUCCCCGCCCACCACUCU), or mutant 2 ins-PRS (5'-UCCACCACUCCCCUCCCACCCCUCU) were synthesized with XbaI restriction sites at both ends. The oligonucleotides were then cloned into the XbaI site of the pCRTM3-CAT vector (Invitrogen, San Diego, CA), downstream the coding sequence of the chloramphenicol acetyltransferase (CAT) reporter gene, and upstream the bovine growth hormone polyadenylation signal. All vectors were control-sequenced using dideoxynucleotide termination sequencing and the Sequenace kit (United States Biochemicals, Cleveland, OH).

Semiquantitative Reverse Transcriptase-PCR-- Lipofection of dispersed islet cells was performed essentially as described previously (22). The cells were transfected with 1 µg of either empty pCR3-CAT vector, pCR3-CAT + wild-type ins-PRS, pCR3-CAT + ins-PRS mutant 1, or pCR3-CAT + ins-PRS mutant 2 and maintained in culture for 48 h. The cells from each of the four dishes were then exposed for 24 h to 2.8 or 28 mM glucose, with our without 5 µg/ml actinomycin D.

The cells were collected from the previous step, and the RNA was isolated using the UltraspecTM Total RNA Isolation reagent. The You-Prime First-strand Beads kit (Amersham Biosciences, Inc.) was used for cDNA synthesis. The sequences of the PCR primers were CAT forward, 5-GAATGCTCATCCGGAACT; CAT reverse, 5'-CCAGGGTCAAGGAAGGCACGG; glyceraldehyde-3-phosphate dehydrogenase forward, 5'-GACCCCTTCATTGACCTCA; and glyceraldehyde-3-phosphate dehydrogenase reverse, 5'-CCTTCTCCATGGTGGTGAA. When analyzing samples treated with actinomycin D, 30 cycles were required to see PCR products in the exponential phase. However, for samples not treated with actinomycin D, 25 cycles were sufficient. The PCR products were run in an 1.5% agarose gel and stained with ethidium bromide for quantification of 28 S rRNA.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Insulin mRNA Is Highly Abundant in Rat beta -Cells-- Using real-time PCR, insulin mRNA contents of in vitro cultured rat pancreatic islets were quantified. We first assessed basal and non-stimulated insulin mRNA levels by preculturing the islets for 24 h at a substimulatory glucose concentration and in the absence of serum. At these basal conditions, we observed that a beta -cell contains 40,000-50,000 insulin mRNA molecules and that insulin mRNA is 60-80 times more frequent than the messenger for beta -actin (Fig. 2B). In line with this, a short term (1 h) stimulation with a high glucose concentration did not increase the contents of insulin mRNA (Fig. 2B). Insulin has recently been reported to potently stimulate insulin gene transcription (8-10). However, addition of 5 µg/ml insulin did not affect insulin mRNA contents (Fig. 2B). These insulin mRNA estimates are based upon the assumption that the yield and efficiency of the RNA extraction and cDNA synthesis procedures are 100%. Our results might therefore be underestimates.

Next, we quantified insulin mRNA contents in response to a long term (24 h) glucose and serum stimulation. The insulin mRNA contents of control islets dropped to ~20,000/beta -cell (Fig. 2C). This is not surprising, because prolonged culture without glucose and serum (24 h + 24 h) is known to result in beta -cell apoptosis (23). The 24-h high glucose stimulation increased insulin mRNA contents to ~100,000/beta -cell (Fig. 2C). Also the ratio insulin mRNA to beta -actin mRNA was markedly increased (Fig. 2C).

Having established that insulin mRNA is highly abundant and only slowly increased in response to glucose, we next addressed the question whether transcriptional or post-transcriptional mechanisms mediate the regulatory effect of glucose. For this purpose, islets were precultured in the presence of serum and high glucose to bring the insulin mRNA contents up to high levels. Next, some of the islets were transferred to a low glucose-containing medium with or without actinomycin D. As expected, a 16-h incubation at a low glucose concentration promoted a small (35%) decrease in insulin mRNA (Fig. 2D). Interestingly, inhibition of RNA synthesis did not decrease insulin mRNA contents and the drop induced by low glucose was of the same magnitude in the presence as in the absence of actinomycin D (Fig. 2D). This correlates well with previous findings showing that actinomycin D does not markedly reduce insulin mRNA levels (5). This is possibly explained by inhibition of synthesis of insulin mRNA degrading factors, which would mask the inhibiting effect on insulin gene transcription (5). On the other hand, beta -actin mRNA did not decrease in response to low glucose and the actinomycin D-induced decrease was more pronounced than that of insulin mRNA (Fig. 2D). Consequently, the low glucose-induced decrease in the insulin mRNA/beta -actin mRNA ratio was of the same relative magnitude both with and without actinomycin D (Fig. 2D). These findings are in line with the previously established insulin mRNA half-life of 29 h at a low glucose concentration, 77 h at a high glucose concentration, and a beta -actin mRNA half-life of 9 h (5, 24).

A 55-60-kDa Protein Binds to the Ins-PRS-- The findings that glucose-induced changes in insulin mRNA stability control insulin mRNA contents prompted us to next investigate the mechanisms that regulate insulin mRNA stability. Probing for specific binding to the pyrimidine-rich insulin mRNA 3'-UTR sequence (ins-PRS), we observed binding of a 25-bp ins-PRS RNA oligonucleotide to a cytosolic protein, both in liver and islet cells. This binding resulted in a cross-linked complex with the combined molecular mass of 65-70 kDa (Fig. 3, A-C). If it were assumed that the RNA oligonucleotide increases the molecular mass of the complex with 10 kDa, the molecular mass of the RNA-binding protein would be 55-60 kDa. This binding was not observed in the absence of uv cross-linking, nor when a mutated RNA oligonucleotide, in which four centrally located C were replaced by A (ins-PRS mutant 3), was used (Fig. 3A). In liver cells, there was also prominent binding to the ins-PRS RNA oligonucleotide by a 40-kDa protein (Fig. 3A). The identity of this protein is not known, but the MW corresponds well to PCBP, which has been reported to bind to the pyrimidine-rich sequence of TH mRNA (25). Binding of the 40-kDa protein to the ins-PRS RNA oligonucleotide was, however, not consistently observed in islet cells (Fig. 3, B and C).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 3.   Binding activity to the ins-PRS RNA oligonucleotide in liver and rat islet extracts. A, rat liver extract was incubated with 32P-labeled wild-type or mutant 3 ins-PRS RNA oligonucleotide. 11 mM DTT was added to some of the samples. Following the binding reaction, some of the samples were uv-cross-linked and analyzed by SDS-PAGE. The arrowhead to the right indicates the position of the 65-70-kDa protein-RNA oligonucleotide complex. Below this complex can also be seen the 50-kDa protein-RNA oligonucleotide complex. B, islet cytosolic extracts were incubated with wild-type ins-PRS RNA oligonucleotide with or without 11 mM DTT and with different concentrations of the molecular cross-linker suberic acid bis(N-hydroxysuccinimide ester). The arrowhead to the right indicates the position of the 65-70-kDa protein-RNA oligonucleotide complex. C, rat islets were incubated for 60 min at 1 or 28 mM glucose. Cytosolic extracts were then prepared and allowed to bind to wild-type ins-PRS RNA oligonucleotide in the presence or absence of DTT. Each sample was subsequently divided into two aliquots, of which one was uv-cross-linked and the other was not (D). Non-cross-linked samples were analyzed by non-denaturing gel electrophoresis. E, islet cytosol extracts from rat and human islets were incubated with rat ins-PRS or human ins-PRS 32P-labeled RNA oligonucleotides, respectively. Binding reactions were analyzed by non-denaturing gel electrophoresis.

The Binding Activity of the 55-60-kDa Protein to Ins-PRS Is Stimulated by Reducing Agents and Glucose-- Using cytosolic extracts from non-stimulated rat pancreatic islets, we observed that the reducing agents DTT (Fig. 3B) or beta -mercaptoethanol (data not shown) increased binding of the 55-60-kDa protein to ins-PRS. The enhancing effect of DTT was dose-dependent and reached maximum at 5-10 mM (data not shown). The increased binding of the 55-60-kDa protein to ins-PRS in response to DTT was also observed when binding reactions were analyzed by non-denaturing gel electrophoresis (Fig. 3D). In this case, binding was visualized by retardation of the radioactive RNA oligonucleotide, and the intensity of the retarded band corresponded well to the intensity of the 65-70-kDa protein-RNA oligonucleotide complex observed in parallel cross-linking experiments (Fig. 3, C and D). The effect of reducing agents was not as clear in islet homogenates stimulated with a high glucose concentration as compared with non-stimulated islets (Fig. 3, C and D). Instead, the ins-PRS binding activity of glucose-stimulated islets was enhanced in the absence of DTT and not further increased in the presence of DTT. These findings suggest that the ins-PRS binding activity is maximally stimulated in the presence of DTT and that differences observed in binding activity in the absence of DTT may reflect the in vivo activity of the 55-60-kDa protein. Thus, by expressing ins-PRS binding activity as the ratio binding activity -DTT/+DTT, we correct for differences in total amount of the 55-60-kDa protein present in islet samples. When analyzing the effect of glucose, it was found that the ins-PRS binding activity in rat islet cytosol was significantly increased by 28 mM, but not by 5 mM glucose (Fig. 4). In nuclear extracts, both 5 and 28 mM glucose increased ins-PRS binding activity as compared with no glucose (Fig. 4). Thus, glucose-induced stabilization of insulin mRNA is paralleled by increased binding of the 55-60-kDa protein to ins-PRS.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 4.   Glucose increases ins-PRS binding activity in both rat islet cytosol and nuclei fraction. A, isolated rat islets were incubated for 60 min with different glucose concentrations and then fractionated into nuclei and cytosol. The different fractions were incubated with the 32P-labeled ins-PRS RNA oligonucleotide, with and without DTT, and then separated with non-denaturating gel electrophoresis. Ins-PRS binding activity was expressed as ratio between the shifted ins-PRS-protein complex without and with DTT. Results are mean ± S.E. for six to seven observations. * denotes p < 0.05 versus indicated control using two-way analysis of variance and Bonferroni's test. B, photograph showing a typical experiment.

Also human insulin mRNA 3'-UTR contains a pyrimidine-rich motif (Fig. 1B). To determine whether binding in human islet cytosol extracts to the human ins-PRS occurs, we analyzed binding reactions by non-denaturing gel electrophoresis. It was observed that a similar gel retardation product was present in human islet extracts as in rat islet extracts (Fig. 3E). This indicates that a similar insulin mRNA 3'-UTR-protein complex is formed in human islets as in rat islets.

The 55-60-kDa Ins-PRS Binding Protein Is Probably PTB-- To determine the identity of the ins-PRS-binding protein, we performed supershift analysis using antibodies specific for hnRNP-K, PCBP, and PTB. The antibodies against hnRNP-K and PCBP did not generate a supershift (Fig. 5A, results not shown). However, two different PTB monoclonal antibodies specifically abolished the ins-PRS/protein complex, an effect that was not observed with control ascites fluid (Fig. 5A). This indicates that antibody binding to PTB blocks PTB binding to the ins-PRS RNA oligonucleotide.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 5.   PTB is probably the ins-PRS-binding protein. A, islet cytosolic extracts were incubated with normal rabbit serum (lane 2), control ascites fluid (lane 3), PCBP antiserum (40) (lane 4), or anti-PTB monoclonal antibodies 3 or 6 (19) (lanes 5 and 6) for 20 min. 32P-Labeled ins-PRS RNA oligonucleotide was then added. Complexes were separated by non-denaturating polyacrylamide gel electrophoresis. B, islet proteins were separated by SDS-12% PAGE and transferred to a filter. The left lane shows an immunoblot with a PTB antibody (IB). The right lane shows Northwestern hybridization using a 32P-labeled ins-PRS RNA oligonucleotide (NW). C, electromobility shift assay was performed, and the gel was cut in different slices. The proteins in this gel slices were then eluted and separated with a SDS-12% PAGE and transferred to a membrane. PTB was detected with the anti-PTB-3 mouse monoclonal antibody. Lane 1 is whole islet extract, lanes 2 and 4 are ins-PRS complex position, lane 3 and 5 are below ins-PRS complex position, lanes 6 and 7 are above ins-PRS complex position. Lanes 1-3 and 6 are with ins-PRS probe and remaining lanes are without.

The Northwestern technique was utilized to probe for ins-PRS binding activity of proteins immobilized to a nitrocellulose filter. We observed ins-PRS binding activity of a renatured protein, which migrated to the same position as PTB (Fig. 5B).

Further evidence in support for PTB as the ins-PRS-binding protein was obtained by analyzing the presence of PTB at the position of the ins-PRS-protein complex in a non-denaturing electromobility shift assay gel. By eluting proteins from above, at and below the position of the ins-PRS-protein complex, we observed PTB immunoreactivity at the complex position in samples with ins-PRS probe present during the binding reaction, but not in samples without (Fig. 5C). The remaining PTB immunoreactivity was located above and not below the position of the ins-PRS-protein complex. These results indicate that the fraction of PTB that binds the ins-PRS RNA oligonucleotide alters its three-dimensional conformation so that it migrates faster in a non-denaturing gel.

PTB and Ins-PRS Stability Is Not Affected by DTT or Glucose-- To exclude the possibility that increased binding of PTB to ins-PRS is due to altered stability in response to DTT or glucose, islet cell homogenates were incubated for 50 min in homogenization buffer with or without 11 mM DTT. Samples were then analyzed by immunoblotting using the anti-PTB-3 antibody and counterstained with Amido Black. It was observed that the in vitro stability of PTB (Fig. 6A) and ins-PRS (Fig. 6B) was not affected by the addition of DTT. In addition, islets were incubated for 1 h in medium containing 2.8 or 28 mM glucose, and the amount of expressed PTB was examined by immunoblotting. We could not observe any differences in PTB expression between the two groups (Fig. 6C), indicating that a 1-h incubation period is not sufficient to alter PTB contents.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 6.   PTB and ins-PRS stability are not affected by DTT or glucose. A, islet cell homogenates were incubated for 50 min with or without 11 mM DTT as described under "Experimental Procedures" and as shown in Figs. 4 and 5. Samples were analyzed by immunoblotting using the anti-PTB-3 monoclonal antibody (upper panel). Total protein was visualized by Amido Black staining (lower panel). B, the 32P-labeled ins-PRS RNA oligonucleotide was incubated as described above and analyzed by 15% PAGE followed by autoradiography. C, islets were incubated for 60 min in 2.8 or 28 mM glucose and then homogenized in SDS/beta -mercaptoethanol sample buffer for immunoblot and Amido Black analysis as given above. Results are representative for two independent experiments.

Inhibition of PTB Binding to Ins-PRS Results in mRNA Destabilization-- Mutation of the critical pyrimidines to purines resulted in abolished binding of PTB to ins-PRS in vitro (Fig. 3A). To assess whether mRNA stability is affected by PTB binding to ins-PRS in vivo, we lipofected dispersed rat islet cells with pCRTM-CAT vector with or without wild-type or mutated ins-PRS. In the presence of actinomycin D, we observed that the reporter gene mRNA containing the wild-type rat insulin I ins-PRS was equally abundant as the mRNA lacking ins-PRS (Fig. 7A). However, a mutation of one of the pyrimidines to a purine in the PTB core-binding site resulted in a marked destabilization of the mRNA, whereas a mutation of a purine to a pyrimidine outside the core-binding site had no effect (Fig. 7A). Similar results were obtained in cells incubated in the absence of actinomycin D (Fig. 7B), indicating that transcription of the reporter gene was not affected by the ins-PRS mutation. In cells expressing wild-type ins-PRS, there was no increase in reporter gene mRNA levels in response to glucose.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 7.   Mutation of ins-PRS core-binding site leads to reporter CAT mRNA destabilization. Rat islet cells were transfected with four different constructs: the empty pCRTM3-CAT vector, the pCRTM3-CAT vector with wild-type, mutant 1, or mutant 2 ins-PRS inserted into the 3'-UTR. Two days after the transfection, the islets were incubated for 24 h at 2.8 or 28 mM glucose with (A) or without (B) 5 µg/ml actinomycin D. Reverse transcriptase-PCR was performed for CAT mRNA, glyceraldehyde-3-phosphate dehydrogenase mRNA, and beta -actin mRNA. Results are mean ± S.E. for three to four experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

To our knowledge, this is the first study to quantify insulin mRNA in isolated pancreatic islets. At physiological conditions, i.e. in the presence of serum, the beta -cell content of insulin mRNAs was at least 40,000-100,000 molecules, depending upon the glucose concentration of the culture medium. This finding is in agreement with the early and indirect assessment (6), which indicated a beta -cell insulin mRNA content of 50,000-150,000 molecules. A typical mammalian cell contains ~360,000 mRNAs in its cytoplasm (26). Assuming that the same number applies to the beta -cell, insulin mRNA would constitute up to 30% of all mRNA, which correlates well with the percentage of insulin protein synthesized (1).

We did not observe any increase in insulin mRNA in response to a short term (60 min) glucose stimulation. This is, however, not surprising considering that insulin mRNA is vastly abundant in beta -cells. The transcriptional output of insulin mRNA by the two insulin genes present in rat has not been determined experimentally. However, a theoretical calculation of the maximal insulin mRNA synthesis rate tells us that no more than 2500 transcripts/h are produced. This assessment is based upon an elongation rate of 30 nucleotides per second and that 10 RNA polymerases transcribe each insulin gene simultaneously. Although this is most likely an overestimate, it is far from the net increase of 40000 molecules, which is the minimum number of molecules necessary to double the insulin mRNA content of low glucose cultured islets in 1 h. In our hands, the insulin mRNA content is only slightly decreased by a 16 h glucose withdrawal. The same decrease was observed in islets with inhibited RNA polymerase activity. This indicates that control of insulin mRNA stability contributes significantly to the regulation of insulin mRNA levels. Indeed, it is generally agreed that the contents of abundant and long lived messengers are subject to post-transcriptional, rather than transcriptional control. This view is challenged by Leibiger and co-workers (8-10), who report that insulin mRNA contents are increased up to 5-fold in response to a 60-min glucose stimulation. The reason for the apparent incompatibilities between the present work and the work by the Leibiger group is unclear.

Although glucose is known to specifically increase insulin mRNA stability (5), little is hitherto known of the molecular mechanisms underlying this event. However, a recent report identified the 3'-UTR of insulin mRNA as critical for control of messenger stability (11). The UUGAA sequence, located between the polyadenylation signal and the polyadenylation site, was suggested to be important because of its conservancy (11). Alternatively, a closer analysis of the 3'-UTR of rat insulin mRNA (Fig. 1A) shows that the region just up-stream of the polyadenylation signal and downstream of the termination codon contains a pyrimidine-rich sequence, with similarities to the PTB (27) and PCBP (12, 28) consensus binding sequences (Fig. 1A). Protein binding to 3'-UTR pyrimidine-rich segments of for example TH and erythropoetin mRNA has been implicated in both constitutive and regulated stability control of the messenger (25, 29). In line with this notion, we have presently observed specific binding of a 55-60-kDa protein to the ins-PRS RNA oligonucleotide. Moreover, mutation of one cytidine to an adenosine in the ins-PRS, which probably prevented protein binding, resulted in marked destabilization of the CAT reporter gene mRNA. This is in line with the work by Wicksteed et al., (11) in which it was shown that the 3'-UTR of insulin mRNA contains stability determinants that mediated a decreased reporter messenger stability when expressed in hepatocytes. This raises the possibility that destabilizing elements of the insulin RNA messenger are masked by beta -cell-specific protein binding to the ins-PRS sequence.

We presently observe that a high glucose concentration, which increases insulin mRNA contents by stabilizing the messenger, stimulated protein binding to ins-PRS. This indicates that regulated protein binding to the ins-PRS element could be a necessary event in glucose-mediated insulin mRNA stabilization. On the other hand, levels of the reporter gene mRNA remained unaffected after introduction of the wild-type ins-PRS as well as after culture at a high glucose concentration. Assuming that dispersed and transfected islet cells respond to glucose as normal islet cells do, it may be that the presence of ins-PRS is not sufficient for glucose-induced stabilization of messenger stability. Thus, there may be a requirement of other cis-acting mRNA elements to obtain full control of glucose-induced changes in mRNA stability. The induced stability of TH mRNA in response to hypoxia is for instance dependent of protein interactions with both the 3'-UTR and the coding region of the mRNA (29).

Using specific antibodies, we have presently observed that the ins-PRS-binding protein is probably PTB. It is not clear why PCBP1 or PCBP2, which both are present in islet cells (results not shown) and which may bind ins-PRS in liver cells, do not bind ins-PRS in islet cell homogenates. PCBP is thought to bind TH mRNA, either at the PCBP consensus binding sequence present in rat TH mRNA (12) or/and at the PCBP-hypoxia-inducible protein-binding site present in human TH mRNA (28) (Fig. 1A). The rat ins-PRS sequence is quite similar to these PCBP-binding sites (Fig. 1A). Thus, it is reasonable to assume that PCBP, at least in liver homogenates, could bind ins-PRS. On the other hand, one or two putative PTB-binding sites are easily identified in rat ins-PRS (Fig. 1A). In addition, pyrimidine-rich sequences similar to the PTB consensus binding site, but not to the PCBP sites, seem to be present in insulin mRNA of most species with known 3'-UTR sequences (Fig. 1B). Taken together, this supports our finding that PTB is the main ins-PRS-binding protein and that this event is evolutionarily conserved.

Species with no ins-PRS are frog, hagfish, and chimpanzee. The frog and particularly the hagfish are evolutionary distant species that both have insulin mRNA 3'-UTRs that are several hundred bases long, suggesting that these mRNAs utilize other mechanisms for messenger stability control. The chimpanzee, however, has lost 48 bp of its insulin gene due to a deletion at a site just after the reading frame (30). This results in a very short 3'-UTR without any pyrimidine-rich motif. Had it been possible to perform experimental studies with chimpanzee islets, it would have been very interesting to determine whether insulin mRNA levels in the chimpanzee are governed by the same signals as in rodent and human islets. Type 2 diabetes mellitus has been observed in the chimpanzee and may be more frequent than expected (31).

The main known function of PTB is to inhibit mRNA splicing (32). In addition, PTB is thought to play an important role in events such as cap-independent translation (33), RNA polyadenylation, (34) and RNA localization (35). The PTB-binding site in insulin mRNA is located just upstream of the polyadenylation signal, and it is not unlikely that PTB, in addition to regulation of mRNA stability, is involved in polyadenylation, transport, and/or translation. Moreover, PTB exists in three different isoforms, with differential alternative splicing activity, and PTB homologues with cell type-specific expression patterns have recently been identified (36). Consequently, the possibility exists that PTB isoforms and the different PTB homologues have overlapping but distinct RNA binding specificities and that a specific PTB isoform or homologue is expressed in beta -cells with the purpose to modulate insulin mRNA levels.

Although PTB mRNA expression is up-regulated about five times in the beta -cell line MIN6, in response to a 24-h glucose stimulation (15), we could not detect any differences in protein expression after a 1-h incubation at different glucose concentrations. This suggests that acute alterations in the PTB binding activity is regulated by post-translational modifications rather than by increased PTB gene expression. Furthermore, PTB is known to interact with other members of the hnRNP family such as hnRNP-E2 (PCBP 2), -K, and -L, which are all expressed in islets (Refs. 33 and 37, present results). Thus, the interaction of PTB with additional RNA-binding proteins may be necessary events in glucose-mediated regulation of insulin mRNA stability.

In summary, we have identified an interaction between the rat insulin I 3'-UTR and the protein PTB, an event that may be necessary for glucose-induced stabilization of insulin mRNA. Future studies will hopefully identify additional proteins and cis-acting elements, which co-operate in mediating a high insulin mRNA stability and availability for translation. Finally, it is possible that disturbances of the insulin mRNA metabolism contribute to the development of diabetes mellitus. Interestingly, the chromosomal localization of the PTB gene has been assigned to chromosome 14-23-p24.1 (38), which is in close proximity to the IDDM11 locus in humans (39).

    ACKNOWLEDGEMENTS

The excellent technical assistance of Ing-Marie Mörsare and Ing-Britt Hallgren is gratefully acknowledged.

    FOOTNOTES

* This work was supported by grants from the Swedish Medical Research Council (12X-109, 12X-11564, 72P-12995), the Swedish Diabetes Association, the Nordic Insulin Fund, the Juvenile Diabetes Foundation International, and the Family Ernfors Fund.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Medical Cell Biology, Uppsala University, Biomedicum, P. O. Box 571, SE-751 23 Uppsala, Sweden. Tel.: 46-18-4714212; Fax: 46-18-556401; E-mail: Nils.Welsh@medcellbiol.uu.se.

Published, JBC Papers in Press, November 5, 2001, DOI 10.1074/jbc.M108340200

    ABBREVIATIONS

The abbreviations used are: UTR, untranslated region; PTB, polypyrimidine tract-binding protein; PCBP, poly(C)-binding protein; TH, tyrosine hydroxylase; ins-PRS, insulin mRNA 3'-UTR pyrimidine-rich sequence; DTT, dithiothreitol; CAT, chloramphenicol acetyltransferase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Ashcroft, S. J., Bunce, J., Lowry, M., Hansen, S. E., and Hedeskov, C. J. (1978) Biochem. J. 174, 517-526
2. Welsh, M., Scherberg, N., Gilmore, R., and Steiner, D. F. (1986) Biochem. J. 235, 459-467
3. Brunstedt, J., and Chan, S. J. (1982) Biochem. Biophys. Res. Commun. 106, 1383-1389
4. Nielsen, D. A., Welsh, M., Casadaban, M. J., and Steiner, D. F. (1985) J. Biol. Chem. 260, 13585-13589
5. Welsh, M., Nielsen, D. A., MacKrell, A. J., and Steiner, D. F. (1985) J. Biol. Chem. 260, 13590-13594
6. Giddings, S. J., Chirgwin, J., and Permutt, M. A. (1985) Diabetologia 28, 343-347
7. Itoh, N., Sei, T., Nose, K., and Okamoto, H. (1978) FEBS Lett. 93, 343-347
8. Leibiger, I. B., Leibiger, B., Moede, T., and Berggren, P.-O. (1998) Mol. Cell 1, 933-938
9. Leibiger, B., Moede, T., Schwarz, T., Brown, G. R., Kohler, M., Leibiger, I. B., and Berggren, P. O. (1998) Proc. Natl. Acad. Sci. U. S. A. 4, 9307-9312
10. Leibiger, B., Wahlander, K., Berggren, P.-O., and Leibiger, I. B. (2000) J. Biol. Chem. 275, 30153-30156
11. Wicksteed, B., Herbert, T. P., Alarcon, C., Lingohr, M. K., Moss, L. G., and Rhodes, C. J. (2001) J. Biol. Chem. 276, 22553-22558
12. Holcik, M., and Liebhaber, S. A. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2410-2414
13. Wang, X., Kiledjian, M., Weiss, I., and Liebhaber, S. A. (1995) Mol. Cell. Biol. 15, 1769-1777
14. Valcarcel, J., and Gebauer, F. (1997) Curr. Biol. 7, 705-708
15. Webb, G. C., Akbar, M. S., Zhao, C., and Steiner, D. F. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 5773-5778
16. Andersson, A. (1978) Diabetologia 14, 397-404
17. Eizirik, D. L., Welsh, N., and Hellerstrom, C. (1993) J. Clin. Endocrinol. Metab. 76, 399-403
18. Chan, S. J., Noyes, B. E., Agarwal, K. L., and Steiner, D. F. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 5036-5040
19. Czyzyk-Krzeska, M. F., Dominski, Z., Kole, R., and Millhorn, D. E. (1994) J. Biol. Chem. 269, 9940-9945
20. Grossman, J. S., Meyer, M. I., Wang, Y. C., Mulligan, G. J., Kobayashi, R., and Helfman, D. M. (1998) RNA (N. Y.) 4, 613-625
21. Stefanovic, B., Hellerbrand, C., Holcik, M., Briendl, M., Aliebhaber, S., and Brenner, D. A. (1997) Mol. Cell. Biol. 17, 5201-5209
22. Saldeen, J., Curiel, D. T., Eizirik, D. L., Andersson, A., Strandell, E., Buschard, K., and Welsh, N. (1996) Diabetes 45, 1197-1203
23. Hoorens, A., Van de Casteele, M., Kloppel, G., and Pipeleers, D. (1996) J. Clin. Invest. 98, 1568-1574
24. Chen, M., Schnermann, J., Smart, A. M., Brosius, F. C., Killen, P. D., and Briggs, J. P. (1993) J. Biol. Chem. 268, 24138-24144
25. Czyzyk-Krzeska, M. F., and Bendixen, A. C. (1999) Blood 93, 2111-2120
26. Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., and Watson, J. D. (1994) Molecular Biology of the Cell , Third Ed. , p. 369, Garland Publishing, Inc., New York
27. Singh, R., Valcarcel, J., and Green, M. R. (1995) Science 268, 1173-1176
28. Czyzyk-Krzeska, M. F., and Beresh, J. E. (1996) J. Biol. Chem. 271, 3293-3299
29. Paulding, W. R., and Czyzyk-Krzeska, M. F. (1999) J. Biol. Chem. 274, 2532-2538
30. Seino, S., Bell, G. I., and Li, W-H. (1992) Mol. Biol. Evol. 9, 193-203
31. Rosenblum, I. Y., Barbolt, T. A., and Howard, C. F., Jr. (1981) J. Med. Primatol. 10, 93-101
32. Wagner, E. J., and Garcia-Blanco, M. A. (2001) Mol. Cell. Biol. 21, 3281-3288
33. Kim, Y. K., Hahm, B., and Jang, S. K. (2000) J. Mol. Biol. 304, 119-133
34. Moreira, A., Takagaki, Y., Brackenridge, S., Wollerton, M., Manley, J. L., and Proudfoot, N. J. (1998) Genes Dev. 12, 2522-2534
35. Cote, C. A., Gautreau, D., Denegre, J. M., Kress, T. L., Terry, N. A., and Mowry, K. L. (1999) Mol. Cell. 4, 431-437
36. Wollerton, M. C., Gooding, C., Robinson, F., Brown, E. C., Jackson, R. J., and Smith, C. W. J. (2001) RNA (N. Y.) 7, 819-832
37. Kamma, H., Portman, D. S., and Dreyfuss, G. (1995) Exp. Cell Res. 221, 187-196
38. Raimondi, E., Romanelli, M. G., Moralli, D., Gamberi, C., Russo, M. P., and Morandi, C. (1995) Genomics 27, 553-555
39. Field, L. L., Tobias, R., Thomson, G., and Plon, S. (1996) Genomics 33, 1-8
40. Blyn, L. B., Towner, J. S., Semler, B. L., and Ehrenfeld, E. (1997) J. Virol. 71, 6243-6246


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
M. Xu, J. R. McCarrey, and N. B. Hecht
A cytoplasmic variant of the KH-type splicing regulatory protein serves as a decay-promoting factor for phosphoglycerate kinase 2 mRNA in murine male germ cells
Nucleic Acids Res., November 10, 2008; (2008) gkn800v1.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
M. Xu and N. B. Hecht
Polypyrimidine Tract Binding Protein 2 Stabilizes Phosphoglycerate Kinase 2 mRNA in Murine Male Germ Cells by Binding to Its 3'UTR
Biol Reprod, June 1, 2007; 76(6): 1025 - 1033.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
C. Evans-Molina, J. C. Garmey, R. Ketchum, K. L. Brayman, S. Deng, and R. G. Mirmira
Glucose Regulation of Insulin Gene Transcription and Pre-mRNA Processing in Human Islets
Diabetes, March 1, 2007; 56(3): 827 - 835.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
L. Van Lommel, K. Janssens, R. Quintens, K. Tsukamoto, D. Vander Mierde, K. Lemaire, C. Denef, J.-C. Jonas, G. Martens, D. Pipeleers, et al.
Probe-Independent and Direct Quantification of Insulin mRNA and Growth Hormone mRNA in Enriched Cell Preparations
Diabetes, December 1, 2006; 55(12): 3214 - 3220.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. E Cerf
Transcription factors regulating {beta}-cell function.
Eur. J. Endocrinol., November 1, 2006; 155(5): 671 - 679.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Pautz, K. Linker, T. Hubrich, R. Korhonen, S. Altenhofer, and H. Kleinert
The Polypyrimidine Tract-binding Protein (PTB) Is Involved in the Post-transcriptional Regulation of Human Inducible Nitric Oxide Synthase Expression
J. Biol. Chem., October 27, 2006; 281(43): 32294 - 32302.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
V. Poitout, D. Hagman, R. Stein, I. Artner, R. P. Robertson, and J. S. Harmon
Regulation of the Insulin Gene by Glucose and Fatty Acids
J. Nutr., April 1, 2006; 136(4): 873 - 876.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
C. Le Sommer, M. Lesimple, A. Mereau, S. Menoret, M.-R. Allo, and S. Hardy
PTB Regulates the Processing of a 3'-Terminal Exon by Repressing both Splicing and Polyadenylation
Mol. Cell. Biol., November 1, 2005; 25(21): 9595 - 9607.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
M. Baudouin-Legros, A. Hinzpeter, A. Jaulmes, F. Brouillard, B. Costes, P. Fanen, and A. Edelman
Cell-specific posttranscriptional regulation of CFTR gene expression via influence of MAPK cascades on 3'UTR part of transcripts
Am J Physiol Cell Physiol, November 1, 2005; 289(5): C1240 - C1250.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
K Hamano, M Awaji, and H Usuki
cDNA structure of an insulin-related peptide in the Pacific oyster and seasonal changes in the gene expression
J. Endocrinol., October 1, 2005; 187(1): 55 - 67.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
N. H. Ing
Steroid Hormones Regulate Gene Expression Posttranscriptionally by Altering the Stabilities of Messenger RNAs
Biol Reprod, June 1, 2005; 72(6): 1290 - 1296.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
P. M. Florez, O. M. Sessions, E. J. Wagner, M. Gromeier, and M. A. Garcia-Blanco
The Polypyrimidine Tract Binding Protein Is Required for Efficient Picornavirus Gene Expression and Propagation
J. Virol., May 15, 2005; 79(10): 6172 - 6179.
[Abstract] [Full Text] [PDF]


Home page